Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06388564 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT06388564 is a Phase 2 study of Chronic Graft Versus Host Disease that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 120 participants, roughly in line with the 112-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06388564, a Phase 2 study of Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • DRUG Ruxolitinib
  • DRUG Corticosteroids
  • DRUG Axatilimab

Study Locations (20)

California

  • City of Hope Medical Center - Duarte
  • University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic - Los Angeles
  • Stanford Cancer Center - Stanford

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Weill Cornell Medicine - New York
  • Mount Sinai Hospital - New York

Colorado

  • University of Colorado Cancer Center - Aurora
  • Colorado Blood Cancer Institute - Denver

Illinois

  • Northwestern University - Chicago
  • The University of Chicago Medicine - Chicago

Ohio

  • Cleveland Clinic - Cleveland
  • The Ohio State University - Columbus

Arizona

  • Mayo Clinic Hospital - Phoenix

Connecticut

  • Smilow Cancer Center-Yale - New Haven

Florida

  • Mayo Clinic Jacksonville - Jacksonville

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-10-11
Est. Completion 2029-12-01
Phase Phase 2

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06388564

The ClinicalTrials.gov registry entry for NCT06388564 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 112-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 3 interventions - of which Ruxolitinib is the first listed.

NCT06388564 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Colorado.

Frequently Asked Questions

What is clinical trial NCT06388564 about?

NCT06388564 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease". This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

What is the current status of trial NCT06388564?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-10-11. Estimated completion is 2029-12-01.

What conditions does trial NCT06388564 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT06388564?

The interventions under investigation include: Ruxolitinib (DRUG), Corticosteroids (DRUG), Axatilimab (DRUG).

Who is sponsoring clinical trial NCT06388564?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06388564 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.